NEWS
NOVA SCOTIA WOUND CARE INNOVATION 'A FRESH START' FOR DIABETIC ULCER PATIENTS
Left to right: Dr. Paul Gratzer (CSO, DeCell), Sean Margueratt (CEO, DeCell) and Lindsay Burke (QE II Health Sciences Centre)
September 25th, 2024
At the Multi-Disciplinary Leg Ulcer Clinic (MDLUC) at Halifax’s QEII Health Science's Centre, a small-scale test-and-try of a local wound care technology is having large-scale impacts on the patients participating in the trial.
As a clinical champion, clinical nurse specialist Lindsay Burke has been applying a new type of wound healing product called DermGEN™, made by Nova Scotia-based DeCell Technologies.
"This is a fresh start,” Burke said. “The motivation around being able to offer something different is extraordinary for these patients, especially those dealing with chronic wounds.”
ALBERTA WOUND CARE CLINICIANS USING DERMGEN™ TO TREAT NON-HEALING WOUNDS
December 1st, 2024
DermGEN™ is currently being utilized in a growing number of clinics and hospitals across Alberta. To date, Westview Health Centre (Stoney Plain), Grande Prairie Regional Hospital and QEII Ambulatory Care Centre (Grande Prairie), Red Deer Community Health (Red Deer), Grey Nuns Hospital (Edmonton) and the Misericordia Community Hospital (Edmonton) are actively using DermGEN™ to treat non-healing wounds such as Diabetic Ulcers, Vascular Ulcers, and Pilonidal Cyst ulcers with more wound types to come.
With the excellent results obtained in treating these non-healing wounds, Alberta Health Services (AHS)—responsible for Wound Product procurement in the province—is currently reviewing DermGEN™ for adoption on their formulary list. In the meantime, DeCell Technologies is working closely with wound care clinicians to supply demand for DermGEN™ in the province.
TORONTO GENERAL HOSPITAL CARRY OUT PILOT PROJECT ON DERMGEN™
August 1st, 2024
A pilot study being conducted at the Toronto General Hospital will provide evidence to show that DermGEN™ may be an effective solution to treat Diabetic Foot Ulcers (DFUs). The study is led by Dr. Graham Roche-Nagel, Head of Vascular Surgery, and is being carried out in the Wound Care Clinic of the hospital. The study is funded through a grant from the Peter Monk Cardiac Centre Innovation Committee.
DECELL ON THE RADIO
January 28th, 2020
Dr. Paul Gratzer (CSO of DeCell) is interviewed by Sheldon MacLeod on the Sheldon MacLeod Show, News 95.7 Halifax on Jan. 28th, 2020 about using DermGEN™ to treat First Nations people with diabetic foot ulcers.
DECELL TECHNOLOGIES OBTAINS FIRST EVER IN THE WORLD PATENT PROTECTION
November 4th, 2020
DeCell Technologies has now obtained patents for it's novel and innovative prECM™ decellularization technology in the U.S., Canada, and five countries in the E.U. (UK, France, Spain, Germany and Italy). These patents include process protection and for the first time ever—composition of matter protection defining the quality of decellularized tissues produced by the prECM™ process. Further, the patents also secure DeCell's novel liquid-based soft tissue sterilization that eliminates the need for using tissue disrupting radiation or energy based sterilization methods.
DECELL STRIKES KEY PARTNERSHIPS
November 9th, 2018
DeCell Technologies Inc. and RegenMed—Ontario’s Premiere Tissue Bank—have signed partnership agreements to manufacture DermGEN™ for both domestic and international sales. RegenMed will both manufacture and distribute DermGEN™ in Canada while also manufacturing DermGEN™ for the International markets. I These agreements allow DermGEN™ to enter the healthcare market place so that clinicians can have an advanced, cost effective solution to treat chronic and acute wounds.
DECELL FINALIST IN 2014 DISCOVERY AWARDS
November 20th, 2014
DeCell Technologies was selected as 1 of 3 finalists in the Innovation Category for the 2014 Discovery Awards and has been selected again as a finalist in the Innovation category for the 2015 Discovery Awards.
REGENMED ANNOUNCES LAUNCH OF DERMGEN™ IN CANADA IN PARTNERSHIP WITH DECELL TECHNOLOGIES
November 6th, 2019
RegenMed—Ontario’s Premiere Tissue Bank located in Thunder Bay, Ontario— and DeCell Technologies Inc. have launched the sale of DermGEN™ for the Canadian marketplace. RegenMed will manufacture and distribute DermGEN™ in Canada.
DECELL VOTED BEST PRESENTING COMPANY FOR EARLY STAGE GROWTH
June 17th, 2014
DeCell Technologies Inc. was voted as the Best Presenting Company for Early Stage Growth at the 2014 Atlantic Venture Forum.
A huge thank you to our sponsors, keynote speakers, panelists, presenting companies, investors, industry advisory board, and general delegates for making the 2nd annual Atlantic Venture Forum a tremendous success! We look forward to seeing you again at our 2015 Forum happening on June 16 & 17, 2015! The Atlantic Venture Forum was pleased to host 26 of the hottest early and growth stage companies on the Atlantic coast. We look forward to watching these companies excel and wish them all the best!
Congratulations to the winners of the 2014 Atlantic Venture Forum.